Loss Causation In The S.D.N.Y.

What is necessary to adequately plead loss causation in a securities fraud case continues to be the subject of contention in the S.D.N.Y., with a number of decisions addressing the issue over the past year. The New York Law Journal has an article (via law.com – free regist. req’d) on yet another loss causation decision in DeMarco v. Robertson Stephens, Inc., 2004 WL 512232 (S.D.N.Y. Jan. 9, 2004), the securities class action against Robertson Stephens over its Corvis Corp. stock recommendations.

The suit alleges that Robertson Stephens’ analysts made buy recommendations for Corvis stock to prop up the price until the firm and some of its executives could sell off their pre-IPO shares in the company (i.e., a variation on a “pump-and-dump” stock manipulation). The alleged scheme was revealed to the market when a May 2001 article in the New York Times reported the discrepancy between Robertson Stephens’ public recommendations and the sales by its executives. In his opinion, District Judge Lynch notes that the price of Corvis stock dropped 16% within a few days of the article.

On the issue of loss causation, the defendants argued that the plaintiffs’ loss was due to the general market downturn in telecommunications stock, not any alleged misrepresentations. The court agreed that the plaintiffs could not merely allege that the price of Corvis shares had been inflated to establish loss causation (there is a circuit split on this issue), holding that “it is unlikely that loss causation could be adequately alleged in every fraud-on-the-market case that successfully pleads transaction causation because in cases where an unforseeable intervening event causes the plaintiffs’ loss, there is no causal nexus between the loss and the misrepresentation.” In the instant case, however, the court found that “the bursting of the Corvis stock bubble could reasonable be construed, at least in part, as the market’s correction of an inflated stock price, pumped up in part by defendants’ false statements about its opinions.”

The court took pains to distinguish the case from the facially similar cases against Merrill Lynch that have been dismissed by Judge Pollack. On the issue of loss causation, Judge Lynch noted that, in contrast to the Merrill Lynch cases, “in this case there is evidence that disclosure of defendants’ scheme caused a further decline in the price of Corvis stock, even after the overall bubble had burst.”

Holding: Motion to dismiss Rule 10b-5 claim denied. A motion to dismiss the insider trading claim against a Robertson Stephens executive, however, was granted.

Quote of note: “On the facts in this case, the Court must conclude that plaintiffs have adequately alleged loss causation because the decline in stock price was a forseeable consequence of defendants’ fraudulent statements that allegedly inflated the price, because in an efficient market, revelation of the misrepresentations will lead inexorably to a price correction.”

Leave a comment

Filed under Motion To Dismiss Monitor

Biotech’s Disclosure Issues

Biotechnology companies are frequent defendants in securities class actions, with the plaintiffs’ allegations often focusing on statements related to the new drug approval process. An article in today’s Boston Globe notes that the Food and Drug Administration (“FDA”) and the SEC “are in talks to develop new guidelines on cooperation” concerning disclosure issues. Last summer, the FDA announced that it has begun making referrals to the SEC when it believes its discussions with a company are being misrepresented to the public markets.

Quote of note: “Just how the FDA and SEC should interact is among the most sensitive issues for biotechnology companies. Their fortunes depend largely on showing investors they are making progress getting approvals for drugs that can cost hundreds of millions of dollars to research. Yet many executives believe that the two agencies work at cross-purposes. While securities rules require wide disclosure, repeating all of the technical detail the FDA conveys about an experimental drug can make a stock extremely volatile, said Carl B. Feldbaum, president of the Biotechnology Industry Organization, a trade group in Washington. ‘I think we need to come up with a coherent system where biotech CEOs aren’t cross-cut, like logs, between the FDA and the SEC,’ Feldbaum said.”

Leave a comment

Filed under All The News That's Fit To Blog

The Atlanta Bar Speaks Out

The Atlanta Journal-Constitution has a feature article on securities class actions. The article profiles the viewpoints of two prominent local securities litigators.

Quote of note: “A fraction of the 200-plus public companies in Georgia have been sued by shareholders in recent years. But the list includes names like Coca-Cola, BellSouth, Mirant, WestPoint Stevens, and most recently, Amvescap’s Invesco Funds Group, and Friedman’s, one of the largest retail jewelry chains in the country. All are defendants in pending cases.”

Leave a comment

Filed under All The News That's Fit To Blog

Short Whoppers Do Count

The Ninth Circuit has issued an opinion in Employee Teamsters Local Nos. 175 and 505 Pension Trust Fund v. Clorox Co., 2004 WL 32963 (9th Cir. Jan. 7, 2004) that addresses discovery, the PSLRA’s safe harbor for forward-looking statements, and scienter issues.

An interesting part of the opinion deals with the plaintiff’s contention that the lower court “incorrectly held that knowingly false statements made by [an officer defendant] during her April 22 conference call are not actionable as long as they are short, and that it improperly relied on limited and general cautions to protect Clorox under the PSLRA’s safe harbor and the ‘bespeaks caution’ doctrine.” The Ninth Circuit disagreed, finding the basis for the district judge’s holding was that the forward-looking statements were accompanied by meaningful cautionary language, not the relative length of the statements. Although plaintiffs argued that the lower court should not have considered cautionary language contained in Clorox’s Form 10-K filing in making this determination, the appellate court found that the officer defendant had referenced the risk factors in the Form 10-K during the call and “the PSLRA does not require that the cautions physically accompany oral statements.”

Holding: Affirming grant of partial summary judgment and judgment on the pleadings.

Quote of note: “It is with respect to these statements that the court observed that [the officer defendant] ‘spoke only a couple of sentences and provided an approximate timetable.’ Investors submit that the court’s holding that ‘short whoppers don’t count’ is error, but we read its decision as turning on context rather than word count.”

Leave a comment

Filed under Appellate Monitor

Who Benefits From Class Action Reform?

The New York Lawyer has an article (via law.com – free regist. req’d) on the Class Action Fairness Act, which looks like it has a chance of passing in the Senate this year. The legislation applies some of the reform concepts in the PSLRA and SLUSA to all class actions. Notably, class actions meeting certain jurisdictional criteria would have to be heard in federal court. As in the field of securities class actions, one of the beneficiaries of the legislation will be large, national plaintiffs’ firms that have the resources to bring these cases.

Quote of note: “The burden on federal judges arising from any legislation that moves class actions to the federal courts has raised concerns among judicial administrators who express concern about the additional caseloads. Because of the added delays and expenses, the cumulative effect of the legislation may cultivate a new generation of stronger plaintiffs’ firms that can match their counterparts in size and expertise.”

Leave a comment

Filed under All The News That's Fit To Blog

Tut Systems Settles

Tut Systems, Inc. (Nasdaq: TUTS) has announced the preliminary settlement of the securities class action pending against the company in the N.D. of California (the company is also settling a related derivative case brought in California state court). According to an article on the settlement in the Oakland Tribune, Plaintiffs had alleged that the company’s financial results for the second and third quarters of 2000 “were false and misleading because the company failed to report a major recall of one of its products in the summer of 2000 that resulted in improperly recognized revenues on sales of defective products that were returned during the recall.”

The settlement of the securities class action, which is still subject to court approval, is for $10 million. The settlement of the derivative case involves Tut’s adoption of certain corporate governance measures and the payment of plaintiff’s legal fees and expenses. Both payments will be made by Tut’s insurance carrier.

Leave a comment

Filed under Settlement

Plaintiffs’ Bar Goes Global

As previously reported in The 10b-5 Daily, the number of securities class actions filed against foreign issuers has been on the rise. The Recorder has an article (via law.com – free regist. req’d) discussing this trend and the challenges posed by the cases.

Quote of note: “The suits represent a clash of business cultures. Few nations have financial regulations as stringent as those of the United States, and none has a plaintiffs bar as active. While American companies have grown used to investor class actions, viewing them as a cost of doing business, European executives see them differently.”

Leave a comment

Filed under All The News That's Fit To Blog

Discovery Of Wells Submissions, Loss Causation, And The IPO Allocation Cases

The WorldCom and Initial Public Offering securities litigations in the S.D.N.Y. are generating judicial opinions on a wide variety of topics, with the plaintiffs frequently getting the better of the argument. Two more opinions have come down from Judge Scheindlin in the IPO allocation cases over the holidays.

Discovery of Wells Submissions

On December 24, the court issued an opinion and order addressing whether “Wells submissions” to the SEC are discoverable in subsequent litigations. The target of a SEC investigation is permitted to file a written submission, known as a Wells submission, with the agency to respond to contemplated charges. The plaintiffs were seeking discovery of Wells submissions made by the underwriter defendants in connection with the SEC’s investigation of the same IPO allocation practices at issue in the current litigation. Although the Wells submissions contained offers of settlement, the court found that they are not “settlement material” and, in any event, they are relevant to the current litigation and therefore discoverable.

Quote of note: “Offers of settlement, however, are not intrinsically part of Wells submissions, which were intended to be ‘memoranda to the SEC presenting arguments why an enforcement proceeding should not be brought.’ To the extent that a respondent may make a settlement offer, that offer is typically clearly identified and thus easily severable from the remainder of the submission.”

Holding: The underwriter defendants are ordered to produce their Wells submissions to plaintiffs on or before January 20, 2004.

The New York Law Journal has an article (via law.com – free regist. req’d) on the decision and the Securities Litigation Watch has a post.

Loss Causation

On December 31, the court issued an order and opinion addressing a motion for judgment on the pleadings by the underwriter defendants. The underwriter defendants argued that the Rule 10b-5 claims against them should be dismissed in light of the Second Circuit’s recent decision on the pleading of loss causation in securities fraud cases. In Emergent Capital, the Second Circuit held that allegations of artificial price inflation, without more, do not suffice to plead loss causation. (The 10b-5 Daily has posted about the decision and the current circuit split on this issue.)

In the IPO allocation cases, the underwriter defendants “allegedly required or induced their customers to buy shares of stock in the aftermarket as a condition of receiving initial public offerings stock allocations.” This conduct allegedly caused the plaintiffs to purchase the stock at an artificially inflated price. The plaintiffs have brought claims, based on different provisions of Rule 10b-5, for (1) market manipulation and (2) material misstatements and omissions.

Although the Emergent Capital decision requires more than price inflation to adequately plead loss causation (e.g., a corrective disclosure revealing the fraud and causing a stock price decline), the court noted that it is a material misstatements and omissions case. Market manipulation, the court argued, is simply different.

“A market manipulation is a discrete act that influences stock price. Once the manipulation ceases, however, the information available to the market is the same as before, and the stock price gradually returns to its true value. . . In market manipulation cases, therefore, it may be permissible to infer that the artificial inflation will inevitably dissipate. That being so, plaintiffs’ allegations of artificial inflation are sufficient to plead loss causation because it is fair to infer that the inflationary effect must inevitably diminish over time. It is that dissipation — and not the inflation itself — that caused plaintiffs’ loss.”

The court offers no citations for this analysis and it certainly reaches some broad (and potentially controversial) conclusions. As for the remaining misstatements and omission claims, the court concedes that Emergent Capital is directly on point, but simply bootstraps the claims into its earlier loss causation analysis: “The content of Underwriters’ misstatements was, in essence: ‘this is a fair, efficient market, unaffected by manipulation.’ In fact (according to plaintiffs), the market was manipulated. For the reasons discussed [] above, that market manipulation was a cause of plaintiffs’ loss. Therefore, the misstatements that concealed that manipulation also were a cause of plaintiffs’ loss.” But if the plaintiffs have brought separate fraud claims based on alleged misstatements, don’t they need to establish that the alleged misstatements, separate and apart from the market manipulation, caused a loss? Apparently not.

Holding: Motion for judgment on the pleadings denied.

Leave a comment

Filed under IPO Allocation Cases, Motion To Dismiss Monitor

Fourth Circuit Breaks Silence On Scienter

To survive a motion to dismiss, the PSLRA requires plaintiffs bringing a securities fraud claim to plead facts establishing a “strong inference” that the defendants acted with scienter (i.e., fraudulent intent). There are two components to this analysis: (1) what is the substantive standard for scienter; and (2) what must a plaintiff allege to meet the “strong inference” pleading requirement. Until last week, the U.S. Court of Appeals for the Fourth Circuit had declined to take a position on either of these issues. Not anymore.

In Ottmann v. Hanger Orthopedic Group, 2003 WL 22992292 (4th Cir. Dec. 22, 2003), the court joined every other circuit in holding that scienter may be established by pleading not only intentional misconduct, but also recklessness (although it must be “severe recklessness [that] is, in essence, a slightly lesser species of intentional misconduct”). Having established the substantive standard, the court turned to what a plaintiff must plead to meet the PSLRA’s “strong inference” pleading requirement.

The court found that “Congress ultimately chose not to specify particular types of facts that would or would not show a strong inference of scienter [as part of the PSLRA].” As a result, the court concluded that a “flexible, case-specific analysis is appropriate in examining scienter pleadings.” Although facts establishing “motive and opportunity to commit fraud (or lack of such facts) may be relevant to the scienter inquiry, the weight accorded to those facts should depend on the circumstances of each case.”

In applying this flexible analysis to the instant case, the court found that there were insufficient facts demonstrating that any of the alleged misstatements were the product of reckless or intentional conduct (as opposed to negligence). Moreover, the court noted that the plaintiffs failed to allege that the individual defendants had any personal motive to make the alleged misstatements, “such as to facilitate personal sales of Hanger stock.” Instead, plaintiffs argued that the defendants were motivated to misrepresent Hanger’s financial situation so as to maintain the company’s positive relationships with its creditors, avoid additional interest payments, and promote future acquisitions. The court concluded that other courts “have repeatedly rejected these types of generalized motives — which are shared by all companies — as insufficient to plead scienter under the PSLRA.”

Holding: Affirm the dismissal of complaint.

Quote of note: “We therefore conclude that courts should not restrict their scienter inquiry by focusing on specific categories of facts, such as those relating to motive and opportunity, but instead should examine all of the allegations in each case to determine whether they collectively establish a strong inference of scienter.”

Addition: Note that the facts of the case do not allow the Fourth Circuit to address an important issue. Based on the analysis in the opinion, it appears clear that the court could have affirmed the dismissal of the complaint based on the lenient Second Circuit pleading standard, as it has in other cases. See Phillips v. LCI Int., Inc. 190 F.3d 609 (4th Cir. 1999). Instead, the court chose to adopt and apply a new pleading standard in a case where the plaintiffs did not allege any personal motive to commit securities fraud (e.g., stock sales by the individual defendants). District courts in the Fourth Circuit are left with no practical guidance on what “weight” the appellate court thinks should be given to those types of allegations in determining whether a strong inference of scienter has been plead.

Leave a comment

Filed under Appellate Monitor

Gaming Lottery Settles

The securities class action against Gaming Lottery Corp., pending in the S.D.N.Y. since 1996, has been preliminarily settled for $1 million (or about 7 cents per damaged share before the deduction of litigation expenses). Plaintiffs allege that the company engaged in misrepresentations concerning its acquisition and operation of Special Manufacturing Inc. In the spirit of the holiday season, the notice of proposed settlement states that plaintiffs’ counsel have declined to apply for any attorneys’ fees.

Quote of note: “Plaintiffs’ Counsel are NOT applying for any attorneys’ fees. Plaintiffs’ Counsel do intend to request the Court to approve a payment to Plaintiffs’ Counsel of $90,000 for reimbursement of expenses incurred in connection with the prosecution of this Action, which is less than 23% of the over $400,000 of expenses actually incurred.”

Leave a comment

Filed under Settlement